CCR3 and ovarian cancer: In our study of circulating basophils from ovarian cancer patients, we selected CCR3 as a marker for basophil identification as it is routinely used in BAT assays and has been previously described as a stable marker, which is highly expressed, independent of the atopic status of the individual or activation state of the basophils.